https://www.reuters.com/business/healthcare-pharmaceuticals/mesoblast-soars-us-fdas-nod-review-lead-drug-candidate-2023-03-08/#:~:text=The%20brokerage%20said%20it%20expects,%241.140%20earlier%20in%20the%20session.
Brokerage Jefferies said it expects "significant" U.S. sales of the drug (nah, therapy) in fiscal 2024.
PS: I will be adding on any pull backs.
This post is not to be construed as investment advice because it is not meant to be.
Significant sales in fiscal 2024
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $3.454M | 3.540M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 84546 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 132684 | 16 |
View Market Depth
| Last trade - 13.35pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |